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Summary The flux of calcium forms an important intracellular messenger system. The bcl-2 oncoprotein isthought to make cells resistant to
a variety of insults, including cytotoxic drugs, by the suppression of apoptosis, which appears to involve the repartitioning of intracellular
calcium. Three drugs that affect calcium pathways and may influence this repartitioning, i.e. dantrolene, azumolene (a water-soluble
dantrolene analogue) and nimodipine, were studied in cell culture, using both a transformed follicle centre lymphoma cell line and primary
culture of lymphoma cells in vitro in a manner that resulted in a growth pattern closely resembling that of the malignancy in vivo. Dantrolene
and azumolene were potent inducers of cell death in both systems reducing the viable cell count by 70-90% in comparison with normal
controls. Nimodipine, in comparison, appeared to have no significant effect. These results obtained in an in vitro setting suggest that further
evaluation of dantrolene and azumolene for the treatment of low-grade non-Hodgkin's lymphoma is warranted.
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The use of calcium channel blocking drugs as therapeutic tools is
well established in clinical practice, but to date they have not
acquired widespead use in the treatment ofmalignant disease. The
realization that calcium flux changes are important in the initiation
ofcell death prompted the study into two groups ofdrugs acting on
different calcium channels; most block the inward flux ofcalcium
by attaching themselves to extracellular voltage-dependent recep-
tors that are present in smooth muscle, myocardium and lympho-
cytes (Katzung and Chatterjee, 1989). Their main role is in the
treatment of cardiovascular disorders, e.g. angina and hyperten-
sion, and the prevention of secondary vasospasm after subarach-
noid haemorrhage. Nimodipine, a dihydropyridine derivative has
been used to block extracellular to cytosolic calcium flux.
Dantrolene sodium, a hydantoin derivative (Miller, 1989), used
in the treatment ofmalignant hyperthermia, binds to the ryanodine
receptor (Smith and Nahorshi, 1993) in skeletal muscle and
prevents the release of calcium from the sarcoplasmic reticulum.
Dantrolene binding sites have been found in neural tissue
(Erausquin et al, 1992; Charles et al, 1993; Smith and Nahorshi,
1993) and also in murine lymphocytes (Garrido et al, 1992). The
natural agonist at the ryanodine receptor appears to be cyclic ADP
ribose (Berridge et al, 1993), which, with members of the inositol
polyphosphate family (Galione et al, 1993; Thorn et al, 1994),
control the influx of calcium from the endoplasmic reticulum to
the cytosol. Interference with the NAD/cyclic ADP ribose
synthesis pathway by cladribine (2 CdA) (Seto et al, 1985), a
profoundly lymphotoxic drug, leads to cell death by induction of
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apoptosis. Azumolene is structurally related to dantrolene but has
a bromogroup substituted for a nitrogroup in the Cl benzene ring
as well as an azo substitution for carbon in the oxazoyl ring.
Azumolene is approximately 30 times more soluble than dantro-
lene (Dershwitz and Sreter, 1990) and in vitro studies in malignant
hyperthermia-susceptible pigs suggest it to be equipotent
(Dershwitz and Sreter, 1990), as do studies in rat soleus muscle
(Leslie and Part, 1989). However, in vivo, dantrolene appears
three times more potent than azumolene (Dhillon et al, 1992) as far
as skeletal muscle relaxation is concerned; in addition, it has been
noted to affect calcium release induced by doxorubicin from
skeletal and cardiac muscle (Tian et al, 1991) where it appeared to
compete directly with doxorubicin.
The partitioning ofcalcium between endoplasmic reticulum and
cytosol seems important in preventing cell death. The apoptotic
suppressor protein bcl-2 has a complex effect on this, the mecha-
nism of which is disputed (Baffy et al, 1993; Lam et al, 1994): in
any event there is agreement that modulation ofcalcium flux may
either induce cell death directly or at least enhance the ability of
cytotoxics to do so.
The studies described here investigate the effect of dantrolene,
azumolene and nimodipine both separately and in combination on
death of lymphoma cells, and their efficacy relative to commonly
used cytotoxic drugs is described. A transformed follicle centre cell
lymphoma cell line DOHH2 was used for the cell line experiments,
and then primary cultured lymphoma cells using the IL-3/IL-10
anti-CD40 stromal cell system (Shamash et al, 1994) were studied.
MATERIALS AND METHODS
Cell line
The DOHH2 cell line (kindly provided by P Kluin, University of
Leiden) is a transformed follicle centre lymphoma with a t(14;18)
expressing bcl-2. This was grown in RPMI 2% supplemented with
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10% fetal calf serum (FCS) (v/v, Gibco BRL, Paisley, UK), peni-
cillin/streptomycin (Gibco) and amphotericin 2.5 mg l-l (Squibb,
Middlesex, UK) at 36°C with 6% carbon dioxide. Cells were grown
in 25 ml of Falcon cell culture flasks (Becton Dickinson) in 10 ml
ofmedium at an initial concentration of 106 ml-'. Cell viability was
assessed using 0.2% trypan blue exclusion. Cell counts were
performed using a haemocytometer or a Coulter counter.
Primary lymphoma culture using the IL-31lL-10
anti-CD40 stromal cell system (Shamash et al, 1994)
Seven low-grade B-cell lymphomas, five centroblastic/centrocytic
and follicular, one small-cell lymphocytic, one lymphoplasma-
cytoid, according to the updated Kiel Classification [five follicle
centre follicular, two small-cell lymphocytic according to the
Revised European American Lymphoma Classification (REAL)]
(Harris et al, 1994), were investigated.
Fresh tissue was taken at biopsy and dissected in a medium of
RPMI 2% with 5% FCS, Hepes 25 mmol 1-' (Gibco) and genta-
micin 50gg ml-' (Roussel Laboratories, Uxbridge, UK). The
suspension was centrifuged on Ficoll Hypaque at 600g for 25 min
at 4°C to isolate the mononuclear fraction. The resting cells were
washed twice in the medium described above before being frozen
at a concentration of 2 x 107 ml-' in a freezing mixture of RPMI
2% with 20% FCS, 10% dimethylsulphoxide (Fluka) and stored in
liquid nitrogen. The cells were resuspended in 2% RPMI with 10%
FCS and penicillin/streptomycin and glutamine. Viability was
assessed by 0.2% trypan blue exclusion. This was greater than
80% in all samples studied.
Cell culture
Mouse fibroblasts (Ltk cells) transfected with the CD32 Fc
receptor (obtained from the American Tissue Culture Collection
with the permission of Dr KW Moore) were grown to confluence
in 24-well culture plates (Becton Dickinson), in 2% RPMI supple-
mented with glutamine and 10% FCS and HAT (Sigma) and then
irradiated to 75 Gy. Seven lymphoma cell suspensions were
thawed from liquid nitrogen. The medium was aspirated and the
lymphoma cells were suspended at a concentration of5 x 105 cells
ml-', 2 ml per well in 24-well plates (Becton Dickinson) in a
growth medium consisting of Iscove's modified Dulbecco's
medium without FCS (Gibco) with 50 mg 1-1 human holotrans-
ferrin; bovine serum albumin 5 g 1-1; bovine insulin 5 mg 1-1 long-
chain fatty acids (cis-9-octadecenoic, all cis-9, 12-octadecadienoic
and hexadecanoic acid all at 1 mg 1-') (all from Sigma), FCS 2%
(v/v), penicillin and streptomycin (Gibco), gentamicin 40 mg 1-1
(Roussel) and amphotericin 2.5 mg 1-' (Squibb), anti-CD40
1 mg 1-' (Seretec), interleukin 3 (IL-3) 20 jg 1-1 and interleukin 10
(IL-10) 100 jg 1-' (both kindly provided by Amgen Biologicals,
Thousand Oaks, CA, USA). Cells were grown for 8-10 days and
monoclonal expansion confirmed using light chain restriction as
assessed by flow cytometry. The percentage of contaminating T
cells was assessed using CD3 FITC. Four wells were treated with
each drug, or drug combination (dantrolene, 4-hydroperoxycyclo-
phosphamide, etc., four wells acted as the untreated control, four
wells as a control for dantrolene containing its diluent only).
Assessment of cell death
Cell death was assessed using 0.2% trypan blue exclusion. Cells
were counted using a haemocytometer.
Preparation of drugs
Dantrolene sodium (kindly provided by Roger Phipps, Proctor and
Gamble Pharmaceuticals, NY, USA, who advised on drug prepara-
tion). For cell line work, dantrolene was dissolved in glycerol
2.5 mg ml-' (6 mmol 1-1), sonicated and stored in the dark. For
primary lymphoma culture, it was prepared in aqueous solution;
50 mg was dissolved in 75 ml ofdistilled water, to this was added
5 g ofmannitol (Sigma). The mixture was sonicated for 2 min and
then 4 mg of sodium hydroxide was added before storing in the
dark for a maximum of48 h (1.675 mmol 1-').
Azumolene was kindly provided by Proctor and Gamble
Pharmaceuticals, NY, USA in the form of a water-soluble white
powder (9.06 mg ml-', 20 mmol 1-1).
Nimodipine (kindly provided by Bayer). This was prepared by
dissolving 4.18 mg of crystalline powder in 10 ml of ethanol and
storing away from light (1 mmol 1-1).
The following concentrations were studied: azumolene (A) 20,
10 and 5 jmol 1-1; dantrolene (D) 60, 30 and 15 ,umol 1-1; nimo-
dipine (N) 1, 0.5, 0.25 gmol 1-1 and combinations: D 60 ,umol 1-1
and N 1 umol 1-1; D 30 mol 1-1 and N 0.5 gmol 1-1; and D
15 ,umol 1-' and N 0.25 ,umol 1-1. The concentrations were chosen
because 40-50,mol 1-1 dantrolene represents the maximum
plasma concentration achieved in humans and 0.7 ,umol 1-l
nimodipine - the therapeutic plasma concentration. Nimodipine
was chosen rather than verapamil as fatal ventricular fibrillation
has been described in animal experiments when the latter has been
combined with dantrolene.
The range of doses of azumolene was selected by starting with
the therapeutic concentrations that had been used in muscle
contraction experiments (5 jmol 1-l) in anaesthetized rats (Dillon
et al, 1992).
The following cytotoxic drugs were used: dexamethasone
(3.4 mg ml-'), vincristine (1 mg ml-') (as solutions from David
Bull Pharmaceuticals), doxorubicin (2 mg ml-') (from Pharmacia)
and 4-hydroperoxycyclophosphamide (4HC) (3 mg ml-') dis-
solved in ethanol. The cytotoxic drugs were incubated at
increasing concentrations, the lowest concentration that resulted in
>25% cell death at 48 h in the DOHH2 cell line was chosen for
studies in primary lymphoma culture.
Cells were grown from five low-grade lymphomas (L211, L304,
L503, LI103 and L1203) for 48-72 h. At this point, dantrolene
(30 or 60gmol 1-1) or 4HC (10 ,umol 1-1) or the combination 4HC
(10 gmol 1-'), vincristine (10 jmol 1-'), doxorubicin (0.1 mmol 1-')
and dexamethasone (10 jmol 1-') were added. The four-drug
regimen was chosen because it represented probably the most
commonly used treatment programme for lymphoma (CHOP:
cyclophosphamide, doxorubicin, vincristine and prednisolone).
4HC was used alone as it represented the alkylating drug
cyclophosphamide, which is used as a single agent to treat low-
grade lymphoma. The cells were analysed 120 h later.
Assessment of P-glycoprotein-mediated drug efflux
Ability to excrete the dye DIOC2 was used as a measure of P-
glycoprotein drug efflux. It was tested in both the DOHH2 cell
line, the primary lymphoma and normal peripheral blood lympho-
cytes as controls (Chaudhary et al, 1992). Cyclosporin A (CsA) at
a concentration of 2 jmol 1-' was used to inhibit P-glycoprotein
function as a positive control.
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Isolation ofblood lymphocytes
Twenty millilitres ofblood was taken from ahealthy volunteer into
a 50 ml Falcon tube (BD) containing 50 jl of heparin (Monoparin
5000 iu ml-'). An equal volume of RPMI 1640 was added to the
tube and mixed by inversion. The diluted blood was divided and
layered on 10 ml ofFicoll Hypaque (Nicomed, Oslo, Norway) and
centrifuged at 600g for 25 min at 25°C. After centrifugation, the
mononuclear cell layer was carefully removed and the cells
washed twice in RPMI.
Lymphocyte dye loading and efflux
Separated lymphocytes were resuspended in 10 ml of RPMI for
30 min with 6 jil of DIOC2 (100 ig ml-') (Molecular Probe,
Eugene, OR, USA) (final concentration 0.06 gg ml-'). Cells were
then washed twice at 4°C to remove extracellular dye and incu-
bated at 37°C for 3 h to permit dye efflux. After incubation, they
were washed with ice-cold media (including centrifugation at4°C)
and the remaining intracellular fluorescence measured by FACS
analysis. Efflux was expressed relative to cells incubated at 4°C
(instead of 37°C) or cells incubated with cyclosporin, both
processes inhibiting dye efflux.
Growth fraction
Cells were fixed in 70% ethanol. Ribonuclease type I (Boehringer
Mannheim) 100 kilounits ml-' and then propidium iodide
50 jig ml-' were added. Propidium iodide fluorescence was
detected at over 580 nm. Cells were gated using forward and light
scatter; 5000 cells were analysed. Cells with propidium iodide
fluorescence in the hypodiploid and diploid GO/GI peak and the
hyperdiploid S + G2 (growth fraction) were determined on red
fluorescence histograms using Lysys II software.
Assessment of Bcl-2 expression by FACS analysis
As this oncoprotein is found in various sites within cells, perme-
abilization ofthe membrane is required. The cells were suspended
in 0.3% Saponin (Sigma) in phosphate-buffered saline (PBSA) for
15 min at 25°C. They were then phenotyped using anti-bcl-2 FITC
(Dako) (10 jil 10-6 cells per 100 jil) in 0.1% saponin solution for
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Figure 1 Effect of different concentrations of dantrolene in the DOHH2 cell
line
30 min at 25°C. They were then centrifuged and resuspended in
PBSA with 1% paraformaldehyde. The negative control (IgG1
mouse FITC, Dako) was similarly prepared. Expression was
described in the form ofmean channel fluorescence vs the control.
Assessment of dantrolene uptake
This was carried out using flow cytometry, as dantrolene auto-
fluoresces in the FL2 band and previous studies have suggested
that autofluorescence may be an indicator of uptake (Flewellen
etal, 1993).
Calculation of viable cell count in primary lymphoma
culture
Four wells in each cultured lymphoma were exposed to each drug
or drugs in combination, or in the case of the controls to the drug
diluents alone. The wells were then aspirated, and the cells pooled
together. The number of viable cells in each group was calculated
by multiplying the total by the percentage viability as assessed by
exclusion of0.2% trypan blue; this also compared to the untreated
control group.
Reproducibility of results and statistical analyses
All cell line work was carried out in duplicate. The primary
lymphoma culture results were single experiments. In each
lymphoma, a drug was applied to four wells of the 24-well plate
and the cells combined from the four wells for analysis.
Different schedules and doses were analysed by a balanced
multiple analysis of variance (Minitab version 10, OH, USA). The
residuals from this analysis were tested to confirm normality of
distribution. This was the case in all (P > 0.1) except for nimodipine
for which P = 0.01. However, as there was clearly no effect with
nimodipine, a non-parametric analysis was not performed.
RESULTS
DOHH2 cell line
Prolongedculture ofDOHH2 cells with dantrolene and/or
nimodipine (Figure 1)
The total viable cell count was analysed at 72 and 156 h. Cell
death was progressive, with a fall in cell numbers apparent by 72 h
for dantrolene compared with the control culture. Only at a high
concentration of 60gmol 1-' were cell numbers actually reduced
compared with the count at time 0. In the lower concentrations, a
retarding effect on cell growth was seen, the numbers rising more
slowly than control (balanced analysis of variance of number of
viable cells in control, 15 gM and 30gM dantrolene cultures,
controlling for dose and time, n = 3, P < 0.001). No evidence of
activity for nimodipine alone was observed (P = 0.645), with
control culture cell count at 156 h = 38.0 ± 3.0 x 105 ml-', dantro-
lene 60 jmol 1-1= 3.0+ 1.0 x 105 ml-', dantrolene 60 jimol 1-' and
nimodipine 1 jimol 1-' = 3.5 ± 0.8 x 105 ml' and nimodipine
1 jimol 1-' alone = 36.0 ± 7.5 x 105 ml-'. At 156 h the cytotoxic
effects of dantrolene alone matched those of the combination of
dantrolene and nimodipine at all concentrations studied (P = 0.859
by analysis ofvariance).
Comparison ofazumolene with dantrolene (see Figure 2)
Cells were incubated for 168 h with three concentrations of
dantrolene (20, 40 and 60 ,umol 1-1) and three concentrations of
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Figure 2 Comparison of single-agent activity of dantrolene and azumolene
in the DOHH2 cell line assessed at 168 h
Table 1 Assessment of P-glycoprotein efflux using DlCO2 fluorescent dye
excretion in culture lymphoma cells with benign peripheral blood lymphocytes
as controls
Percentage of bright cells
(retaining fluorescent dye)
Lymphomas 0 ,umol CSA 2 ,umol CSA
L304 54.8 59.3
L503 81.3 81.4
L1103 91.2 66.2
L1203 59.6 70.1
Peripheral blood lymphocyte control 28.5 93.9
azumolene (5, 10 and 20 gmol 1-'). The maximal efficacy of the
two drugs appeared similar with azumolene appearing three to
four times more potent than dantrolene.
Assessment ofmultidrug resistance - P-glycoprotein using
DIOC2 fluorescent dye extraction
Benign peripheral bloodlymphocytes (controls)
Lymphocyte control cells, incubated at 0°C, had a mean cellular
fluorescence of 2470 units (range 858-9900). Markers were set
about fluorescence distribution for cells incubated at 0°C and, for
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Figure 3 Mean results of primary lymphoma cultures - dantrolene vs 4HC
vs 'CHOP'. Percentage of viable cells vs untreated control
all other incubations, the proportion of cells falling within these
markers was calculated (bright cells).
Across the concentration range for both dantrolene (0.5-
20 j.mol 1-') and nimodipine (0.5-1 gmol 1-1) peripheral blood
lymphocytes showed no difference in drug efflux compared with
control (28-31% cells bright), i.e. not effluxing fluorescent dye.
Higher concentrations of dantrolene could not be assessed using
this method as the compound autofluoresces.
The addition of CsA (an inhibitor of P-glycoprotein) increased
the number of bright cells from 31% to 81% demonstrating the
presence of an active P-glycoprotein pump that was clearly not
affected by dantrolene or nimodipine.
DOHH2 cell line
Of the cells, 95% were bright in the absence of cyclosporin and
85% in the presence of cyclosporin (2 jmol 1-'), suggesting the
absence ofa functional P-glycoprotein system. No effect was seen
with the addition of nimodipine 0-1 gmol 1-1. The autofluores-
cence of dantrolene meant that its effect could not be analysed
using this method.
Primary lymphoma culture
Assessment ofmultidrug resistance - P-glycoprotein using
DIOC2 fluorescent dye efflux
In primary lymphoma cultures incubated with 0 and 2 ,umol 1-'
cyclosporin for 2 h, the difference in bright cells was not significant
Table 2 Lymphoma subtype, growth fraction and bcl-2 expression in primary culture compared with DOHH2 cell line
Lymphoma Subtype Bcl-2 expression
(REAL classification) (percentage vs
Growth fraction IgG1 negative control)
Day 1 Day8 Day 1 Day8
L211 Follicle centre, follicular 7 7 97 36
L304 B-cell small lymphocytic 3 2 0 93
L503 Follicle centre, follicular 6 4 9 35
L802 Follicle centre, follicular 10 NA 4 NA
L903 B-cell small lymphocytic 7 6 92 89
L1103 Follicle centre, follicular 18 23 47 80
Li 203 Follicle centre, follicular 10 11 92 6
DOHH2 cell line Transformed follicle centre lymphoma 40 40 34 34
NA, not available.
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Table 3 Percentages of viabilities using trypan blue exclusion and the percentage of total viable cells vs an untreated control in five primary low-grade
lymphomas treated with dantrolene 30,mol 1-' and 60,mol 1-1, 4HC and 'CHOP' chemotherapy
L211 L304 L503 L1103 L1203
(V%) (T%) (V%) (T%) (V%) (T%) (V%) (T%) (V%) (T%)
Control 97 100 94 100 95 100 95 100 90 100
D-60 76 44 80 42 79 47 81 70 79 64
D-30 93 76 89 44 82 36 89 67 83 64
4HC-10 88 66 70 23 78 33 89 47 74 41
'CHOP' 54 12 56 9 56 12 70 13 58 18
V%, percentage of viable cells in each group as shown by trypan blue exclusion; T%, total number of viable cells in each group shown as a percentage of total
viable cells in control group. D-60, dantrolene 60gmol l-1; D-30, dantrolene 30 tmol l-1; 4HC-10, 4HC 10gmol l-1; 'CHOP', 4HC 10 imol l-1; doxorubicin 0.1
imol l-1; vincristine 1 imol 1-1; dexamethasone 10 gmol 1-1.
[median 70.5% bright vs 68.2% (cyclosporin treated) P = 1.0 (Mann-
Whitney)]. Individual results are presented in Table 1. The quality of
cells meant that this experiment could only be carried out once.
This suggests that the lymphoma cells did not possess a
functional P-glycoprotein system.
The effect ofcalcium channelblockade with dantrolene
alone, 4HC or 'CHOP' chemotherapy in primary lymphoma
cultured cells (Figure 3 and Table 2)
The growth fraction (GF) of the control group was assessed at
8 days and compared with the initial GF of the biopsy material
(Table 2). Bcl-2 expression is also shown and can be seen to vary
between one tumour and another at the start and during culture.
Flow cytometry confirmed light chain restriction and a B-cell
proliferation by CD19 + CD22 staining, suggesting that the malig-
nant cells were proliferating. The percentage of T cells remained
stable during culture (data not shown). Dantrolene uptake into
cells was confirmed by autofluorescence. Dantrolene at 30 and
60,mol 1-1 had similar effects, unlike in the cell line (Figure 3).
Dantrolene appeared equivalent to single-agent 4HC and all
appeared inferior to the four-drug regimen. A table showing the
individual results (Table 3) with the percentage viability of cells
counted in each treated group (V) is shown, as well as the total
viable cell count shown as a percentage of the untreated control
(T). The mean results ofall five primary cultures showing the total
viable cell count in each group as a percentage of the untreated
control is shown in Figure 3.
Dantrolene vs azumolene in three primary lymphoma
cultures (Figure 4)
Three lymphoma cultures were set up as above and dantrolene
60 ,umol 1-1 or azumolene 6 ,umol 1-1 was added for 120 h before
analysis. In the three samples studied, at these concentrations, the
two drugs were equally efficacious.
DISCUSSION
This study was designed to assess the activity of drugs that are
known to affect calcium repartitioning - a process thought to be
important in initiating apoptosis (Baffey et al, 1993). Two drugs,
dantrolene and azumolene, appeared tohave adirectcytotoxic effect,
while the third, nimodipine, appeared not to. This effect was studied
both in a cell line known to produce anti-apoptotic protein bcl-2 and
in low-grade B-cell lymphoma primary cultures, in which bcl-2 is
also present. The cytotoxic activity of dantrolene and azumolene
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Figure 4 The effect of dantrolene vs that of azumolene in three lymphoma
cultures assessed after 120 h continuous incubation
appears independent of the level of bcl-2 in primary lymphoma
culture initially, and indeed the level of bcl-2 varied during culture
between the lymphomas studied; in addition, it appeared to be unre-
lated to the growth fraction. Whetherthe activity ofthese drugs is via
disruption of this system or some other vital calcium-dependent
pathway or indeed may be completely calcium independent remains
an open question, as there is increasing evidence that absolute bcl-2
levels are not as important as the concentration relative to other
members ofthe family, e.g. bax orbcl.
The results of the experiments with the DOHH2 cell line show
that dantrolene has a direct cytotoxic effect, whereas nimodipine
either alone or in combination does not. A dose response to dantro-
lene is seen across the range of 15-60 ,umol 1-'. A cytostatic action
is seen for 30gmol 1-' with the 60 gmol 1-1 being significantly
more effective and cytotoxic. In the primary culture, however, 30
and 60 ,umol 1-1 appear equivalent.
Again, the addition of nimodipine appeared to add little. This
may be because most cytosolic calcium changes depend on reparti-
tioning between endoplasmic reticulum and cytosol rather than
receiving calcium for the extracellular space (Charles et al, 1993).
A similar calcium blocker, verapamil, has been reported to cause
inhibition of B-cell proliferation in vitro and to induce clinical
responses to B-cell chronic lymphocytic leukaemia (CLL) (Berrebi
et al, 1994). It has been suggested that this might be due to tumour
necrosis factor (TNF) release inhibition (Berrebi et al, 1994).
The concentration ofdantrolene required for the observed effects
is higher than in many studies of its actions. Its effects in muscle
contraction depression, both in vitro and in vivo, appear to be
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maximal at the 10 tmol 1-' range (Flewellen et al, 1993). Various
experiments have used concentrations ofup to 300 gmol 1-' (Smith
and Nahorski, 1993). Suppression of intracellular calcium mobi-
lization needed to stimulate gluconeogenesis in rat hepatocytes has
been achieved using 60 ,tmol 1-1 of dantrolene (Koike et al, 1992).
Doses have been given to humans that should produce concentra-
tions in the region of 40-50 lmol 1-' without ill effect (Blank and
Boggs, 1990). High concentrations administered to Beagle dogs
using lyophilized dantrolene/mannitol and sodium hydroxide
showed no effect of the mannitol sodium hydroxide and a 54%
inhibition of skeletal muscle contraction in dantrolene doses
producing levels of55-60 ,umol 1-1, with no effect on heart or blood
pressure (Ellis et al, 1976). Such concentrations appear to be
feasible for investigation.
Azumolene appeared to be a particularly interesting agent in
that it was equipotent to dantrolene in skeletal contraction inhibi-
tion (Dhillon et al, 1992) but three to four times more potent in
suppression oflymphoma proliferation in vitro. The efficacy ofthe
two agents appeared equivalent.
Assessment of the multidrug resistance phenotype was consid-
ered important to rule out the explanation that any effect was
simply due to blockade of the P-glycoprotein pump. In fact, there
was no evidence that either the DOHH, cell line or the primary
cultured cells studied had a functional P-glycoprotein system as
assessed by DIOC2 dye excretion. Indeed, even if they had, it
would fail to explain the direct effect ofdantrolene on the cell line
and primary cultures.
The experiments comparing dantrolene to 4HC to a four-drug
combination 'CHOP' in primary culture demonstrated dantrolene
and 4HC to have equivalent effects. 4HC was chosen as it is a repre-
sentative ofthe alkylator group ofdrugs that appear to be equivalent
to multiagent treatment in vivo in previously untreated low-grade
NHL and remain the standard first-line drugs for the treatment of
low-grade lymphoma (Lister et al, 1978). Although the 'CHOP'-
like four-drug regimen appeared more effective, this may simply be
equivalent to the more rapid response to multidrug treatment
compared with single agents seen in vivo (Homing et al, 1993) as
analysis was carried out at 120 h, rather than over a much longer
period when the results may have tended to converge.
In summary, unexpected single-agent activity ofdantrolene and
azumolene has been demonstrated in low-grade lymphoma, firstly
in a cell line and more importantly in primary lymphoma culture.
In primary culture, dantrolene appears equivalent to 4HC, which
in this system and in vivo has consistent activity; ofnote, however,
the effects are much less impressive than in the cell line. The role
of dantrolene or azumolene as candidate therapies for low-grade
lymphoma warrant further investigation.
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